Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guobang PharmaSHSE:605507 +0.79%81 FCF Margin % is 1.96% as of Jun. 2026, which is 48% below its 10-year median of 3.74. GuruFocus rates SHSE:605507 with a GF Score™ of 81/100 and a GF Value™ of ¥15.67 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 964 Drug Manufacturers companies, Guobang Pharma ranks better than 63.07% on this metric.
The historical data trend for Guobang Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guobang Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guobang Pharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guobang Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Guobang Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guobang Pharma (SHSE:605507) has a FCF Margin % of 1.96% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Guobang Pharma and its competitors. This is 48% below median its historical median of 3.74. According to the industry distribution chart, Guobang Pharma ranks #356 out of 964 companies in the Drug Manufacturers industry, placing it in the top 36.9%.
Is Guobang Pharma's FCF Margin % too high?
Guobang Pharma's current FCF Margin % of 1.96% is 48% below median its 10-year median of 3.74. The Drug Manufacturers industry median FCF Margin % is 2.57. Guobang Pharma's value of 1.96% is 23.7% below this industry median. Based on the distribution chart, Guobang Pharma ranks #356 out of 964 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guobang Pharma has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guobang Pharma's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Guobang Pharma ranks #356 out of 964 companies for FCF Margin %. This puts Guobang Pharma in the upper half of its industry. The industry median FCF Margin % is 2.57. Guobang Pharma's value of 1.96% is 23.7% below this benchmark. While the company's 10-year median is 3.74 vs. the industry median of 2.57, Guobang Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guobang Pharma's current FCF Margin % of 1.96% is 23.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Guobang Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guobang Pharma's current FCF Margin % is 1.96%, which is 48% below median its own 10-year median of 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guobang Pharma stock overvalued right now?
Based on GuruFocus' analysis, Guobang Pharma (SHSE:605507) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥15.67, compared to a current price of ¥17.87 — trading 14% above its estimated fair value. The current FCF Margin % is 1.96%, which is 48% below median its 10-year median of 3.74 and 23.7% below the Drug Manufacturers industry median of 2.57. Guobang Pharma's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Guobang Pharma (SHSE:605507), the current FCF Margin % is 1.96% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guobang Pharma (SHSE:605507) Overvalued in 2026?
Based on GuruFocus' analysis, Guobang Pharma stock appears to be overvalued.
The current stock price of ¥17.87 is trading 14% above its estimated GF Value™ of ¥15.67.
GuruFocus considers Guobang Pharma to be Modestly Overvalued.
Key valuation signals for SHSE:605507:
FCF Margin %: 1.96% (48% below median its 10-year median of 3.74)
GF Value™: ¥15.67 vs. price of ¥17.87 (14% above fair value)
Industry Position: 23.7% below the Drug Manufacturers median (#356 of 964)
No single metric tells the full story. See the SHSE:605507 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guobang Pharma Ltd is engaged in the research and development, production and sales of related products in the field of medicine and animal health products.
81GF Score
Get the complete analysis for SHSE:605507
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605507 has been successfully added to your 
